Trial Profile
An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Oct 2017
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Heart failure
- Focus Diagnostic use
- Acronyms ADMIRE-HF
- Sponsors GE Healthcare
- 24 Jun 2014 New trial record